Financial Performance - The company's operating revenue for Q1 2023 was ¥90,744,669.29, representing a decrease of 24.44% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥7,819,891.42, down 60.15% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,687,735.93, reflecting an 85.35% decline compared to the previous year[5] - Basic earnings per share for Q1 2023 were ¥0.08, down 61.90% year-over-year[6] - Net profit for Q1 2023 was -¥166,119.75, compared to a net profit of ¥17,321,842.35 in Q1 2022, indicating a significant decline[20] - The total equity attributable to shareholders increased to ¥1,239,186,893.62 in Q1 2023 from ¥1,228,605,285.24 in Q1 2022, showing a growth of about 0.5%[18] Cash Flow - The net cash flow from operating activities was -¥17,959,253.73, a significant decrease of 12,727.15% compared to the same period last year[5] - The company reported a net cash flow from operating activities of -¥17,959,253.73 in Q1 2023, contrasting with a positive cash flow of ¥142,227.31 in Q1 2022[22] - The net cash flow from investing activities was -$1,485,469.38, compared to $91,163,278.99 in the previous period, indicating a significant decrease in investment returns[23] - The cash inflow from financing activities was $3,357,000.00, primarily from minority shareholders' investments, while the net cash flow from financing activities was -$570,776.85, compared to $2,557,074.17 previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,371,910,263.46, a decrease of 1.50% from the end of the previous year[6] - The company's current assets totaled ¥509,847,262.66, down from ¥595,076,395.73 at the end of 2022, indicating a decline of approximately 14.3%[14] - The total liabilities decreased to ¥146,973,508.56 in Q1 2023 from ¥170,447,006.45 in Q1 2022, reflecting a reduction of approximately 13.7%[18] - The company's total liabilities were not explicitly stated, but current liabilities included accounts payable of ¥30,358,126.25, down from ¥32,591,057.59, a decrease of about 6.8%[15] Research and Development - Research and development expenses totaled ¥14,264,308.12, accounting for 15.72% of operating revenue, an increase of 3.38 percentage points[6] - The company’s research and development expenses for Q1 2023 were ¥12,842,534.61, a decrease of 13.3% from ¥14,813,078.40 in Q1 2022[18] Inventory and Receivables - The company's accounts receivable stood at ¥232,608,440.91, slightly down from ¥236,164,593.91, showing a decrease of approximately 1.3%[14] - Inventory increased to ¥70,909,307.59 from ¥63,073,696.31, representing an increase of about 12.9%[14] Financial Management - The company is actively managing its financial assets, with trading financial assets reported at ¥107,041,708.13, down from ¥175,536,506.82, a decrease of approximately 39.0%[14] - The company has ongoing investments in various non-current financial assets, totaling ¥164,554,562.25, an increase from ¥147,449,916.08[15] Other Financial Metrics - The weighted average return on equity was 0.63%, a decrease of 0.36 percentage points from the previous year[6] - The company reported non-recurring gains totaling ¥5,132,155.49 for the period[7] - Cash received from sales of goods and services was ¥102,350,362.44 in Q1 2023, down from ¥117,195,663.62 in Q1 2022, a decline of 12.7%[22] - The company reported an increase in investment income to ¥384,247.99 in Q1 2023 from ¥1,389,733.77 in Q1 2022, indicating a decrease of 72.4%[18] Accounting Changes - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[23]

Financial Performance - The company achieved operating revenue of 507.38 million yuan, a year-on-year increase of 15.58%[131]. - The net profit attributable to shareholders decreased by 46.48% to 42.69 million yuan, while the net profit excluding non-recurring gains and losses fell by 34.79% to 40.94 million yuan[131]. - The cash flow from operating activities saw a significant decline of 83.70%, dropping to ¥9.72 million from ¥59.61 million in 2021[18]. - The cost of sales increased by 51.37% to 146.75 million yuan, indicating rising operational costs[133]. - The gross margin for self-produced products was 82.08%, while for purchased products it was 37.23%, indicating a significant difference in profitability[138]. - The company reported a significant increase in manufacturing costs, with manufacturing expenses rising to 1,670.41 million RMB, accounting for 24.43% of total costs, up from 18.6% the previous year[144]. - The company’s total assets increased by 1.98% to ¥1.39 billion at the end of 2022, compared to ¥1.37 billion at the end of 2021[18]. - The company’s core products, LBP and PCR series, account for over 50% of total revenue, indicating reliance on a limited product range[122]. Research and Development - Research and development expenses accounted for 13.57% of operating revenue, an increase of 3.11 percentage points from 10.46% in 2021[20]. - R&D investment reached 6,885.71 million yuan, up 50.01% year-on-year, accounting for 13.57% of operating revenue[31]. - The company achieved a total R&D investment of ¥68,857,064.06, representing a 50.01% increase compared to the previous year[97]. - The number of R&D personnel increased to 186, representing 21.33% of the total workforce, with total R&D compensation reaching RMB 34.12 million[106]. - The company is focusing on automation, standardization, digitization, and intelligence in pathology diagnostics, developing products like the "Love Pathology" APP and real-time sharing systems[118]. Market and Strategic Developments - The company plans to expand its market share by leveraging partnerships with medical alliances and community platforms, targeting grassroots hospitals[177]. - The company is considering strategic acquisitions to enhance its product portfolio, targeting companies with annual revenues of 100 million yuan or more[190]. - The company is actively involved in the development of companion diagnostics, which are essential for ensuring the safety and efficacy of targeted therapies[60][61]. - The company has established a marketing network covering over 2,000 medical institutions across 31 provinces in China[53]. - The company aims to improve the capabilities of grassroots pathology departments by providing training and resources, addressing the significant shortage of 120,000 pathologists in China[173]. Governance and Management - The company has maintained a stable governance structure with no changes in the red-chip architecture during the reporting period[186]. - The total pre-tax remuneration for all directors and senior management during the reporting period amounted to 717.38万元[189]. - The company’s remuneration policy for directors and senior management is based on industry standards and company performance[197]. - The chairman, Cai Xiangting, has been in position since March 17, 2014, and has a background in preventive medicine[189]. - The company has not reported any changes in shareholding for its directors and senior management during the reporting period[187]. Risks and Challenges - The company faces risks related to new product development and registration, which are critical for maintaining its competitive edge in the rapidly evolving in vitro diagnostic industry[119]. - The company is exposed to accounts receivable risks as its business scales, with a potential increase in bad debts if market conditions worsen[126]. - The company faces risks from increasing market competition and potential price declines in its cervical cancer screening products due to industry trends[123]. - The company has outlined potential risks in its annual report, which investors should be aware of[4]. Product Development and Innovation - The company has developed over 700 registered/recorded products related to pathological diagnosis, making it one of the most comprehensive technology platforms in the domestic tumor screening and diagnosis industry[66]. - The company has established a complete product line covering liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), addressing various clinical diagnostic needs[66]. - The company has successfully developed a fully automated IHC staining machine, further expanding its product offerings in the precision diagnosis market[88]. - The company is developing a series of automated pathology equipment and AI-assisted diagnostic systems to enhance diagnostic capabilities and efficiency in pathology departments[173]. - The company has launched an intelligent overall solution for cervical cancer screening, combining cytology reagents, preparation equipment, scanners, and AI interpretation[109]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[190]. - New product launches are expected to contribute an additional 300 million yuan in revenue over the next year[191]. - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online sales[190]. - The company will continue to focus on tumor screening and precision diagnosis, enhancing its pathology business with technologies such as LBP, IHC, FISH, and PCR[174].

证券代码：688393 证券简称：安必平 公告编号：2023-019 广州安必平医药科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2022 年 4 月 21 日(星期五)至 4 月 27 日(星期四)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zqswb@gzlbp.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 广州安必平医药科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 4 月 28 日上午 10:00-11:30 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度的经营 ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 （2022 年 5 月） | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n√现场参观 √其他 | | | | 参与单位名称 久久联创、德胜汇盈基金、富业盛德资产 | | | 时间 2022 | 年 5 月 6 日、5 月 | 11 日、 5 月 19 日 | | | 地点 公司会议室及线上会议 | | | 公司接待人员 | ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 （2022 年 6 月） | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 √其他 | | | | 参与单位名称 九泰基金、成都海天鸿 | | | 时间 2022 | 年 6 月 22 日、 6 | 月 24 日 | | 地点 线上会议 | | | | | 董事会秘书：蔡幸伦 | | | 公司接待人员 | 投资者关系高级经理：陈元元 证券事务代表：杜坤 | | | | 交流的主要问题及答复： | | | | 1 ...

2022 年第三季度报告 证券代码：688393 证券简称：安必平 1 / 18 广州安必平医药科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 131,800,363.60 | 14.90 | 374 ...

Financial Performance - The company reported a total revenue of 100 million CNY for the first half of 2022, representing a year-on-year increase of 15%[11] - The company achieved operating revenue of CNY 242.53 million, a 14.20% increase compared to the same period last year[17] - The company reported a total revenue of RMB 15.3 billion for the first half of 2022, with a net profit of RMB 3.13 billion, representing a year-on-year increase of 12.6%[60] - Net profit attributable to shareholders decreased by 30.81% to CNY 35.21 million, while the net profit excluding non-recurring gains and losses fell by 28.37% to CNY 31.71 million[17] - The net cash flow from operating activities declined by 49.69% to CNY 11.94 million, primarily due to changes in product sales structure and increased sales costs[17] Research and Development - Research and development expenses increased by 30% in the first half of 2022, reflecting the company's commitment to innovation and new technology development[11] - R&D expenditure accounted for 12.90% of operating revenue, an increase of 5.73 percentage points compared to the previous year[17] - The company reported a total R&D expenditure of ¥31,276,582.98, representing a 105.50% increase compared to ¥15,219,824.64 in the previous year[55] - The number of R&D personnel increased to 163, accounting for 20.90% of the total workforce, compared to 20.17% in the same period last year[63] - The company has developed over 580 registered/recorded products related to pathological diagnosis, making it one of the most comprehensive platforms in the domestic tumor screening and diagnosis industry[23] Product Development and Innovation - The company plans to launch two new diagnostic products in Q4 2022, aiming to capture a 10% market share in the new segments[11] - The company launched a series of digital pathology products, integrating cutting-edge technologies such as the internet and big data to enhance diagnostic capabilities[26] - The company has developed an automated sedimentation-based liquid-based cytology system, enhancing diagnostic efficiency and reducing contamination risks[42] - The company has successfully developed an AI-assisted diagnostic product for cervical cytology in collaboration with Tencent, which has received positive feedback in clinical research evaluations[43] - The company has established a comprehensive cervical cancer screening solution, integrating cytology and HPV testing, which has been well-received by clinical practitioners[66] Market Strategy and Expansion - Future outlook includes a projected revenue growth of 25% for the full year 2022, driven by new product launches and market expansion strategies[11] - The company is exploring potential acquisitions to enhance its technology capabilities and expand its market presence in the Asia-Pacific region[11] - The company aims to expand its market presence by developing cost-effective cervical cancer screening solutions for grassroots healthcare institutions[66] - The company has established a marketing network covering 31 provinces, serving nearly 2,000 medical institutions, including over 1,000 tertiary hospitals and more than 700 top-tier hospitals[71] - The company is actively participating in the construction of pathology departments in grassroots medical institutions, promoting the integration of pathology services[27] Financial Management - The company maintains a strong cash position with cash and cash equivalents totaling 50 million CNY as of June 30, 2022[11] - Cash and cash equivalents at the end of the period reached ¥254,402,776.88, representing 18.75% of total assets, an increase of 16.87% compared to the previous year[114] - The company’s investment cash flow turned positive at 46.98 million RMB, a significant improvement from a negative 99.87 million RMB in the previous period[112] - The company’s management expenses surged by 98.73% to 33.63 million RMB, driven by salary adjustments and increased personnel costs[112] - The company’s total liabilities decreased, with accounts payable down by 14.68% to ¥42,455,874.16, indicating improved cash flow management[116] Risk Management - The company has identified key risks including regulatory changes and market competition, which could impact future performance[11] - The company faces risks related to single product reliance, market competition, and potential price declines in its core LBP and PCR product lines, which account for over 50% of revenue[105] - The company has established measures to resolve related party transactions involving the controlling shareholder[138] - The company has a strategy in place to address competition among peers, ensuring compliance with regulations[138] - The company will comply with all relevant laws and regulations regarding share reduction and will announce any reductions in accordance with legal requirements[143] Corporate Governance - The company appointed a new CFO, Hou Quanneng, on May 16, 2022, following the departure of the previous CFO, Yang Zhiliang[126] - The company held its annual general meeting on April 22, 2022, where all resolutions were passed without any objections[123] - The company has implemented a restricted stock incentive plan, approved by the board on April 1, 2022, with details disclosed on April 2, 2022[127] - The controlling shareholder, Cai Xiangting, committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the date of listing[138] - The company has committed to maintaining transparency and accuracy in its financial disclosures to protect investor interests[183] Environmental Responsibility - The company has been recognized as a "Green+" enterprise for its commitment to environmental protection and energy conservation[131] - The company has taken measures to reduce carbon emissions by improving production processes and energy efficiency[132] - The company is not classified as a key pollutant discharge unit and has obtained necessary environmental permits[130] - The company ensures the independence of its subsidiaries to avoid unnecessary related-party transactions, maintaining fair pricing in any unavoidable transactions[200] - The company has established measures to prevent dilution of immediate returns from fundraising activities[175]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 120,089,759.96, representing a year-on-year increase of 20.68%[5] - The net profit attributable to shareholders decreased by 26.40% to CNY 19,624,115.78 compared to the same period last year[5] - Basic and diluted earnings per share were both CNY 0.21, down 27.59% from the same period last year[6] - In Q1 2022, the company's net profit was CNY 17,321,842.35, a decrease of 34% compared to CNY 26,233,758.61 in Q1 2021[19] - The company reported a total profit of CNY 20,986,803.66, down 33% from CNY 31,255,584.08 in the previous year[19] - The total comprehensive income for the period was CNY 17,321,842.35, reflecting a decrease from CNY 26,233,758.61 in the previous year[20] Research and Development - Research and development expenses totaled CNY 14,813,078.40, which is an increase of 143.97% year-on-year, accounting for 12.34% of operating revenue[6] - Research and development expenses increased significantly to CNY 14,813,078.40, compared to CNY 6,071,613.10 in Q1 2021, marking a 144% rise[19] - Research and development expenses increased significantly to CNY 11,278,702.55, up 180.5% from CNY 4,024,853.55 in the same period last year[30] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 142,227.31, reflecting a significant decrease of 90.91% compared to the previous year[6] - The cash flow from operating activities showed a net increase of CNY 142,227.31, a decline from CNY 1,564,154.14 in Q1 2021[23] - The company's cash and cash equivalents at the end of the period totaled CNY 310,322,384.54, down from CNY 662,991,698.93 at the end of Q1 2021[24] - The net cash flow from operating activities in Q1 2022 was -¥3,572,285.51, compared to a positive net cash flow of ¥426,769.10 in Q1 2021, indicating a significant decline[33] - The company's cash and cash equivalents at the end of Q1 2022 stood at ¥290,606,781.98, compared to ¥644,469,476.43 at the end of Q1 2021, reflecting a decrease of approximately 55.1%[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,374,585,523.28, a slight increase of 0.65% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 1,374,585,523.28, slightly up from RMB 1,365,683,854.03 at the end of 2021[16] - Total liabilities decreased to RMB 146,288,394.23 from RMB 155,959,139.08 at the end of 2021, a reduction of 6.5%[17] - The total liabilities increased to CNY 188,998,204.29 from CNY 183,613,066.30 at the end of 2021[28] - The company's equity attributable to shareholders increased to RMB 1,223,626,796.20 from RMB 1,204,002,680.42, reflecting a growth of 1.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,394[9] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Market and Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in the current report[13] - There are no significant mergers or acquisitions reported during the quarter[13] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]

Financial Performance - The company's operating revenue for 2021 was approximately ¥438.99 million, representing a year-over-year increase of 16.93% compared to ¥375.43 million in 2020[22]. - The net profit attributable to shareholders for 2021 was approximately ¥79.78 million, a decrease of 5.86% from ¥84.75 million in 2020[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥62.78 million, down 11.28% from ¥70.76 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately ¥59.61 million, a decline of 34.79% compared to ¥91.43 million in 2020[22]. - The comprehensive gross profit margin for 2021 was 77.92%, a decrease of 1.85 percentage points compared to 2020, primarily due to an increase in the proportion of purchased products[126]. - Revenue from external diagnostic products was 437.44 million yuan, with a gross profit margin of 77.94%, reflecting a year-on-year increase of 16.79%[128]. - Service revenue saw a significant increase of 255.34%, reaching 16.78 million yuan, indicating successful expansion in service offerings[128]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.70 CNY per 10 shares, totaling approximately 25,201,800 CNY, which represents 31.59% of the net profit attributable to shareholders for 2021[6]. - The company’s profit distribution plan has been approved by the board and is pending approval from the shareholders' meeting[6]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company has detailed potential risks in its annual report, which can be found in the section discussing operational conditions and risk factors[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for providing guarantees[9]. - The company has not reported any special arrangements for corporate governance[9]. Research and Development - R&D investment reached 45.90 million yuan, up 65.52% year-on-year, accounting for 10.46% of operating revenue[33]. - The total R&D investment for the year was approximately ¥45.90 million, representing a 65.52% increase compared to the previous year's ¥27.73 million[87]. - The company has established a dedicated R&D team of 148 people, accounting for 21.23% of total employees, and has participated in multiple national and provincial research projects to enhance its technological innovation capabilities[102]. - The company is focusing on enhancing R&D efforts in tumor screening and diagnosis across multiple technology platforms[88]. Market and Product Development - The company has developed a comprehensive solution for cervical cancer screening, integrating cytology and HPV molecular testing, which significantly improves specimen satisfaction and detection rates compared to traditional methods[97]. - The company is actively developing a cervical cytology AI-assisted diagnostic product in collaboration with Tencent, aiming to establish industry standards for cervical liquid-based cytology databases[66]. - The company is focusing on the development of automated, standardized, digitalized, and intelligent pathology departments, integrating cutting-edge technologies such as big data and cloud computing[66]. - The company has developed 570 registered/recorded pathology diagnosis-related products, making it one of the most comprehensive technology platforms in the domestic tumor screening and diagnosis industry[63]. Strategic Partnerships and Collaborations - The company has established a strategic partnership with Tencent AILab to develop AI-assisted diagnostic products for cervical cytology[31]. - The company is exploring collaborative models to enhance pathology services in grassroots hospitals, addressing the uneven distribution of pathology resources in China[75]. - The company has established partnerships with leading pathology experts to enhance its research capabilities and project execution[102]. Risks and Challenges - The company faces risks related to new product development and registration, which are critical for maintaining its market position[111]. - The company anticipates increased market competition and potential price declines for its cervical cancer screening products due to industry maturation[114]. - The company faces risks related to accounts receivable collection due to rapid growth in sales, with accounts receivable aging typically within one year[118]. Governance and Management - The company has maintained a stable leadership structure, with all directors and key technical personnel holding their positions since their appointment dates[181]. - The company has a diverse management team with extensive experience in various sectors, ensuring a robust governance structure[183]. - The board of directors attended 10 meetings in total, with all members present at each meeting[195]. Investment and Acquisitions - The company made significant equity investments in 2021, including 100% ownership in multiple subsidiaries focused on sales and medical diagnostics[154]. - The company is actively expanding its market presence through strategic investments in diagnostic and medical service companies[155]. - The company has established multiple investment partnerships, with ownership stakes ranging from 9.09% to 100% in various entities[154]. Sales and Marketing - The company has established a nationwide marketing network with over 1,900 clients, including 976 tier-three hospitals[169]. - The company is focusing on developing distribution channels, resulting in a faster growth rate in distribution sales compared to direct sales[132]. - The company’s marketing strategy emphasizes a "direct sales as primary, distribution as supplementary" model, enhancing customer engagement through training and technical support[37].

一、 主要财务数据 2021 年第三季度报告 证券代码：688393 证券简称：安必平 广州安必平医药科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 (二)非经常性损益项目和金额 (一)主要会计数据和财务指标 单位：元 币种：人民币 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损 益（包括已计提资产减 | -48,729.55 | 311,449.16 | | | 值准备的冲销部分） 计入当期 ...